Comparison of treatment outcomes in patients with metastatic lung cancer who did or did not develop EGFR T790M mutation.

e21658Background: First-line treatment of lung cancer patients with EGFR mutation with early generation tyrosine kinase inhibitors (TKIs) renders a median progression-free survival (mPFS) of 11 mon...